Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $42.3333.

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, February 3rd. Wedbush upped their price objective on shares of Tyra Biosciences from $37.00 to $53.00 and gave the stock an “outperform” rating in a research report on Friday, February 13th. Barclays started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating for the company. William Blair began coverage on shares of Tyra Biosciences in a research report on Tuesday, February 10th. They issued an “outperform” rating on the stock. Finally, Piper Sandler boosted their target price on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, January 23rd.

Tyra Biosciences Stock Performance

TYRA stock opened at $35.04 on Friday. The company’s 50-day simple moving average is $30.25 and its 200 day simple moving average is $21.20. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $35.96. The company has a market capitalization of $1.89 billion, a PE ratio of -17.43 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). On average, analysts forecast that Tyra Biosciences will post -1.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Robert J. More sold 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 15.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in Tyra Biosciences in the fourth quarter valued at $51,000. Chung Wu Investment Group LLC bought a new position in shares of Tyra Biosciences during the 4th quarter worth about $53,000. Federated Hermes Inc. grew its stake in shares of Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Tyra Biosciences in the 4th quarter valued at about $220,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.